-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, A6x0ee5ST075TXU0XTVsmFihCMiNSCm2b9Z1fHN3MfNRkUV1vcja35KCWE7ktwTM ifP611WCLtkD1ZtIeFcmMg== 0000010427-96-000016.txt : 19960318 0000010427-96-000016.hdr.sgml : 19960318 ACCESSION NUMBER: 0000010427-96-000016 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19950930 FILED AS OF DATE: 19960315 SROS: NYSE FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAUSCH & LOMB INC CENTRAL INDEX KEY: 0000010427 STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851] IRS NUMBER: 160345235 STATE OF INCORPORATION: NY FISCAL YEAR END: 1225 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-04105 FILM NUMBER: 96535356 BUSINESS ADDRESS: STREET 1: ONE BAUSCH & LOMB PLACE STREET 2: P O BOX 54 CITY: ROCHESTER STATE: NY ZIP: 14604-2701 BUSINESS PHONE: (716) 338-6000 MAIL ADDRESS: STREET 1: ONE CHASE SQUARE STREET 2: P O BOX 54 CITY: ROCHESTER STATE: NY ZIP: 14601-0054 10-Q/A 1 10-Q/A THIRD QUARTER 1995 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended Commission File September 30, 1995 Number: 1-4105 BAUSCH & LOMB INCORPORATED (Exact name of registrant as specified in its charter) New York 16-0345235 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) One Bausch & Lomb Place, Rochester NY 14604-2701 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (716) 338-6000 Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No As of September 30, 1995 there were outstanding 57,196,543 shares of Common Stock, consisting of 56,289,554 shares of Common Stock and 906,989 shares of Class B Stock which are identical with respect to dividend and liquidation rights and vote together as a single class for all purposes. PART I - FINANCIAL INFORMATION Item 1. Financial Statements. As more fully described in Note A - "Restatement of Financial Information", 1994 financial information has been restated to reflect the decision to account for shipments under a fourth quarter 1993 U.S. contact lens distributor program as consigned inventory and to record revenues when the products were sold by the distributors to their customers and to reverse the effect of subsequent product returns and pricing adjustments related to this program which had been previously recognized in 1994. Additionally, a restatement was made to correct the improper recording of certain 1993 sunglass distributor sales in Southeast Asia and to reverse related sales returns which had been previously recorded in 1994. Unaudited consolidated financial statements of Bausch & Lomb Incorporated and Consolidated Subsidiaries for the third quarters of 1995 and 1994 are presented on the following pages. The audited balance sheet at December 31, 1994 is presented for comparative purposes. Financial statements for the nine months ended September 30, 1995 have been prepared by the Company in accordance with its usual accounting policies and are based in part on approximations. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial statements in accordance with generally accepted accounting principles have been included. All such adjustments were of a normal recurring nature. BAUSCH & LOMB INCORPORATED AND CONSOLIDATED SUBSIDIARIES STATEMENT OF EARNINGS Dollar Amounts In Thousands - Except Per Share Data
Third Quarter Ended Nine Months Ended Sept. 30, Sept. 24, Sept. 30, Sept. 24, 1995 1994* 1995 1994* Net Sales $476,757 $486,059 $1,477,817 $1,411,072 Costs And Expenses Cost of products sold 205,495 248,019 657,949 675,920 Selling, administrative and general 173,764 178,343 574,707 524,054 Research and development 15,981 14,802 47,634 45,468 ------- ------- --------- --------- 395,240 441,164 1,280,290 1,245,442 ------- ------- --------- --------- Operating Earnings 81,517 44,895 197,527 165,630 ------- ------- --------- --------- Other (Income) Expense Investment income (9,310) (8,553) (28,839) (26,434) Interest expense 11,013 10,182 34,999 29,409 Gain from foreign currency, net 2,294 (1,084) 4,258 (2,222) Gain on Sale of Sports Optics Division - - (35,902) - Litigation Provision - - 16,000 - ------- ------- --------- --------- 3,997 545 (9,484) 753 ------- ------- --------- --------- Earnings Before Income Taxes And Minority Interest 77,520 44,350 207,011 164,877 Provision for income taxes 28,682 14,860 75,744 54,104 ------- ------- --------- --------- Earnings Before Minority Interest 48,838 29,490 131,267 110,773 Minority interest in subsidiaries 5,324 6,113 15,880 17,574 ------- ------- --------- --------- Net Earnings $ 43,514 $ 23,377 $ 115,387 $ 93,199 ------- ------- --------- --------- Retained Earnings At Beginning Of Period $889,578 $913,960 $ 846,245 $ 871,680 Cash Dividends Declared: Common stock, $0.26 and $0.75 per share for 1995 ($0.245 and $0.71 per share for 1994) 14,829 14,527 43,369 42,069 ------- ------- --------- --------- Retained Earnings At End Of Period $918,263 $922,810 $ 918,263 $ 922,810 ======== ======= ========= ========= Net Earnings Per Common Share $ 0.75 $ 0.39 $ 1.98 $ 1.56 ======== ======= ========= ========= Average Common Shares Outstanding (000s) 58,247 59,787 ========= ========= *Results have been restated as more fully described in Note A - "Restatement of Financial Information" See Notes To Financial Statements
BAUSCH & LOMB INCORPORATED AND CONSOLIDATED SUBSIDIARIES BALANCE SHEET Dollar Amounts In Thousands
September 30, December 31, 1995 1994 ASSETS Current Assets Cash and cash equivalents $ 283,930 $ 230,369 Short-term investments, at cost which approximates market 942 2,173 Trade receivables, less allowances of $13,304 and $16,830, respectively 266,608 271,990 Inventories, net 303,958 312,781 Deferred income taxes, less valuation allowance of $17,882 44,651 40,372 Other current assets 103,251 96,281 ---------- --------- 1,003,340 953,966 Property, Plant And Equipment, net 541,223 542,750 Goodwill And Other Intangibles, less accumulated amortization of $91,892 and $77,394, respectively 393,396 395,950 Other Investments 434,753 425,000 Other Assets 127,200 140,065 --------- --------- Total Assets $2,499,912 $2,457,731 ========= ========= LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities Notes payable $ 212,498 $ 252,783 Current portion of long-term debt 99,973 47,788 Accounts payable 64,895 71,718 Accrued compensation 87,789 71,742 Accrued liabilities 247,192 216,956 Federal and foreign income taxes 28,568 15,551 --------- --------- 740,915 676,538 Long-Term Debt, less current portion 231,670 289,504 Other Long-Term Liabilities 139,267 149,094 Minority Interest 429,158 428,208 --------- --------- Total Liabilities 1,541,010 1,543,344 --------- --------- Shareholders' Equity 4% Cumulative Preferred Stock, par value $100 per share - - Class A Preferred Stock, par value $1 per share - - Common Stock, par value $0.40 per share, 60,198,322 shares issued 24,079 24,079 Class B Stock, par value $0.08 per share, 1,278,771 and 1,072,880 shares issued, respectively 102 86 Capital in excess of par value 90,006 90,637 Cumulative translation adjustment 96,004 47,609 Retained earnings 918,263 846,245 --------- --------- 1,128,454 1,008,656 Common and Class B Stock in treasury, at cost, 4,280,550 and 2,278,745 shares, respectively (169,552) (94,269) --------- --------- Total Shareholders' Equity 958,902 914,387 --------- --------- Total Liabilities And Shareholders' Equity $2,499,912 $2,457,731 ========= ========= See Notes To Financial Statements
BAUSCH & LOMB INCORPORATED AND CONSOLIDATED SUBSIDIARIES STATEMENT OF CASH FLOWS Dollar Amounts In Thousands
Nine Months Ended September 30, September 24, 1995 1994* CASH FLOWS FROM OPERATING ACTIVITIES Net earnings $115,387 $ 93,199 Adjustments to reconcile net earnings to net cash provided by operating activities: Depreciation of property, plant and equipment 65,894 62,005 Amortization of goodwill and other intangibles 12,108 12,737 (Increase) decrease in deferred income taxes (6,478) 4,881 Gain on sale of Sports Optics Division, after taxes (20,823) - Provision for litigation expense, after taxes 10,560 - Loss on retirement of fixed assets 3,616 10,460 Exchange loss (gain) 9,804 (3,333) Increase in undistributed earnings of subsidiaries 12,035 4,113 (Increase) decrease in accounts receivable (5,901) 42,413 Increase in inventories (16,417) 1,497 Decrease (increase) in other current assets 12,623 (18,551) Increase (decrease)in accounts payable and accruals 28,136 (48,028) Decrease in tax liabilities (9,812) (2,227) Decrease in other long-term liabilities (10,548) (2,641) ------- ------- Net cash provided by operating activities 200,184 156,525 ------- ------- CASH FLOWS FROM INVESTING ACTIVITIES Payments for purchases of property, plant and equipment (58,046) (63,122) Acquisition of businesses, net of cash and short-term investments acquired (2,564) (27,089) Proceeds from sale of Sports Optics Division, net of cash and short-term investments sold 76,291 - Other investments (9,425) (425,000) Other 8,314 (21,553) ------- ------- Net cash used in investing activities 14,570 (536,764) ------- ------- CASH FLOWS FROM FINANCING ACTIVITIES Repurchases of Common shares (83,248) (11,211) Exercise of stock options 4,764 7,631 Restricted stock awards 2,586 2,399 Net (repayment of) proceeds from issuance of debt (47,436) 46,459 Payment of dividends (42,873) (40,642) ------- ------- Net cash provided by (used in) financing activities (166,207) 4,636 ------- ------- Effect of exchange rate changes on cash, cash equivalents and short-term investments 3,783 23,327 ------- ------- Net increase (decrease) in cash, cash equivalents and short-term investments 52,330 (352,276) Cash, cash equivalents and short- term investments, beginning of period 232,542 546,036 ------- ------- Cash, cash equivalents and short- term investments, end of period $284,872 $193,760 ======= ======= Supplemental disclosures of cash flow information: Cash paid during the period for: Interest $ 37,092 $ 23,836 Income taxes $ 70,365 $ 56,789 *Results have been restated as more fully described in Note A - "Restatement of financial Information". See Notes To Financial Statements
BAUSCH & LOMB INCORPORATED AND CONSOLIDATED SUBSIDIARIES NOTES TO FINANCIAL STATEMENTS NOTE A: Restatement of Financial Information The Company has restated its financial statements for the years ended December 25, 1993 and December 31, 1994. This action was taken as a result of an ongoing investigation which identified uncertainties surrounding the execution of a fourth quarter 1993 contact lens sales program and the improper recording of 1993 sunglass sales in Southeast Asia. In the fourth quarter of 1993 a marketing program was initiated to implement a business strategy to shift responsibility for the sale and distribution of a portion of the U.S. traditional contact lens business to optical distributors. Subsequently, this strategy proved unsuccessful and, in the 1994 third quarter, led to the implementation of a new pricing policy for traditional contact lenses and a decision to accept on a one-time basis returns from these distributors. The investigation of this marketing program disclosed instances where unauthorized terms may have been or were offered which were inconsistent with the stated terms and conditions of the program. The resulting uncertainties relating to the execution of this marketing program led to a decision to restate the 1993 financial statements to account for shipments under the program as consigned inventory and to record revenues when the products were sold by the distributors to their customers and to reverse the effect of subsequent product returns and pricing adjustments related to this program which had been previously recognized in 1994. The investigation of Southeast Asia sunglass sales disclosed that in certain instances distributor transactions recorded as revenues in 1993 had not actually resulted from a sale to those customers, and thus were improperly recorded. The 1993 financial statements have been restated to reverse the improperly recorded sales with a corresponding restatement of the 1994 financial statements to reverse the effect of sales returns previously recognized in that period. In the opinion of management, all material adjustments necessary to correct the financial statements have been recorded. The impact of these adjustments on the Company's financial results as originally reported is summarized below: Dollar Amounts In Thousands - (Except Per Share Data)
Third Quarter Ended Nine Months Ended ---------------------------------------------------- September 24,1994 September 24, 1994 ----------------------------------------------------- As Reported As Restated As Reported As Restated ----------------------------------------------------- Net Sales: Healthcare $298,281 $320,556 $ 891,626 $ 913,901 Optics 151,166 165,503 479,873 497,171 ----------------------------------------------------- Total $449,447 $486,059 $1,371,499 $1,411,072 Business Segment Earnings $ 31,098 $ 54,756 $ 173,431 $ 198,414 ----------------------------------------------------- ----------------------------------------------------- Net Earnings $ 7,689 $ 23,377 $ 76,405 $ 93,199 ------------------------------------------------------ ------------------------------------------------------ Net Earnings Per Share $ 0.13 $ 0.39 $ 1.28 $ 1.56 ------------------------------------------------------- ------------------------------------------------------- Retained Earnings at end of Period $923,661 $922,810 $923,661 $922,810 ------------------------------------------------------ ------------------------------------------------------
NOTE B: Earnings Per Share Net earnings per Common share are based on the weighted average number of Common and Class B shares outstanding during the period, adjusted for the assumed conversion of dilutive stock options. In computing the per share effect of assumed conversion, funds which would have been received from the exercise of options are considered to have been used to purchase Common shares at current market prices, and the resulting net additional Common shares are included in the calculation of average Common shares outstanding. The number of Common shares used to calculate net earnings per Common share were 58,247,318 at September 30, 1995 and 59,787,023 at September 24, 1994. See Exhibit 11 filed with this Report for details regarding the computation of earnings per share. NOTE C: Inventories Inventories consisted of the following: (Dollar Amounts In Thousands)
September 30, December 31, 1995 1994 Raw materials and supplies $ 84,668 $ 79,295 Work in process 22,656 23,985 Finished products 207,142 222,079 -------- --------- 314,466 325,359 Less - Reserve for valuation of certain U.S. inventories at last-in, first- out cost 10,508 12,578 -------- --------- $303,958 $312,781 ======== =========
NOTE D: Property, Plant And Equipment Major classes of property, plant and equipment consisted of the following: (Dollar Amounts In Thousands)
September 30, December 31, 1995 1994 Land $ 22,297 $ 21,474 Leasehold improvements 34,075 32,635 Buildings 390,368 366,003 Machinery and equipment 620,024 587,586 --------- --------- 1,066,764 1,007,698 Less - Accumulated depreciation 525,541 464,948 --------- --------- $ 541,223 $ 542,750 ========= =========
NOTE E: Legal Proceedings In its 1994 Annual Report on Form 10-K and its first and second quarter 1995 Forms 10-Q the Company reported on proposed class actions filed in Pennsylvania, New Jersey, New York and California state courts, alleging that the Company misled consumers in its marketing and sale of Sensitive Eyes Saline and Rewetting Drops, Boston Rewetting Drops and Conditioning Solution and the Company's eyewash product. On September 12, 1995, the Company entered into a stipulation in the New York case, certifying a nationwide class of consumers of Sensitive Eyes Rewetting Drops, Boston Rewetting Drops, Bausch & Lomb Eyewash and ReNu Rewetting Drops for the period May 1, 1989 to June 30, 1995, which is awaiting court approval. A similar action has been moved from federal to state court in California and has been temporarily stayed pending further developments in the New York case. In each of these matters, the Company is defending itself vigorously in part on the basis that the Company's actions were in compliance with applicable FDA regulations. In its 1994 Annual Report on Form 10-K, the Company described proposed shareholder class actions involving purchasers of stock between December 14, 1993 and June 3, 1994 and between June 4, 1994 and January 25, 1995. The suits claim the Company did not fully disclose information about expected future financial results, thus misleading its shareholders. On September 25, 1995, the plaintiffs in these actions consolidated their claims and filed a second amended consolidated complaint. The Company continues to vigorously defend against these claims. Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. This financial review, which should be read in conjunction with the accompanying financial statements, contains management's discussion and analysis of the Company's financial results, liquidity and progress toward stated business objectives. The Company seeks to manage its diverse operations to outperform peer companies on key financial measures such as sales and earnings growth and return on assets and equity. The Standard & Poor's Healthcare Composite Group has been formally adopted as the peer group against which Bausch & Lomb will systematically measure its financial progress. The Company also emphasizes the need for operational stability, predictability and profitability. As more fully described in Note A - "Restatement of Financial Information", 1994 financial information has been restated to reflect the decision to account for shipments under a fourth quarter 1993 U.S. contact lens distributor program as consigned inventory and to record revenues when the products were sold by the distributors to their customers and to reverse the effect of subsequent product returns and pricing adjustments related to this program which had been previously recognized in 1994. Additionally, a restatement was made to correct the improper recording of certain 1993 sunglass distributor sales in Southeast Asia and to reverse related sales returns which had been previously recorded in 1994. The discussion which follows reflects the restated financial information. RESULTS OF OPERATIONS Comparability Of Financial Information Comparisons of 1995 and 1994 third quarter and nine month financial results are complicated by the sale in the 1995 second quarter of the Company's Sports Optics Division, which marketed binoculars, riflescopes and telescopes. That business contributed approximately $35 million and $75 million in revenues for the 1994 quarter and nine-month periods, respectively. Revenues from sports optics reported in the first quarter of 1995 totaled approximately $18 million. Net Sales By Business Segment Bausch & Lomb's results are reported in two business segments. The healthcare segment includes personal health, medical and biomedical products. In the personal health sector, major lines include contact lens care products, eye care solutions, over-the-counter medications, skin care products and oral care products. Medical products include contact lenses and lens materials, prescription pharmaceuticals, hearing aids and dental implants. Biomedical products include purpose-bred laboratory animals for biomedical research, specific pathogen-free eggs for vaccine production, and a variety of biotechnical and professional services provided to the scientific research community. Bausch & Lomb's optics segment includes sunglasses and optical thin film coating services and products. Consolidated reported revenues for the third quarter ended September 30, 1995 were $477 million, a decrease of $9 million or 2% from the 1994 third quarter. Changes in currency exchange rates improved sales comparisons to 1994 by approximately $11 million or 2%. For the first nine months of 1995, net sales of $1,478 million increased $67 million or 5% from the comparable 1994 period. Changes in currency exchange rates improved sales comparisons to the 1994 period by approximately $53 million or 4%. Excluding revenues from the divested sports optics business, consolidated revenues increased 6% and 9% for the quarter and nine-month periods, respectively. The following is a summary of net sales by business segment: Net Sales By Business Segment (Dollar Amounts In Millions)
Third Quarter Nine Months 1995 1994 1995 1994 Healthcare $345.4 $320.6 $1,014.9 $ 913.9 Optics 131.4 * 165.5 462.9 * 497.2 ----- ------ ------- ------- Net Sales $476.8 $486.1 $1,477.8 $1,411.1 *1995 amounts include results for the discontinued sports optics business for the first quarter only.
Healthcare Segment Revenues Revenues in the healthcare segment increased $25 million or 8% over the 1994 third quarter. On a year-to-date basis, healthcare segment revenues advanced $101 million or 11% over the comparable 1994 period. Major product sector revenues as a percentage of total healthcare segment sales follow: Healthcare Segment Net Sales By Product Sector
Third Quarter Nine Months 1995 1994 1995 1994 Personal Health 51% 53% 50% 52% Medical 36% 33% 36% 34% Biomedical 13% 14% 14% 14%
Within the personal health sector, 1995 third quarter revenues improved 2% from the comparable 1994 level. The Company's lines of lens care solutions, including the ReNu and Boston brands, advanced more than 15% in non-U.S. regions. In the U.S., lens care solutions revenues decreased 4%. The Company believes this decline is attributable to a trend for soft lens care solutions toward lower retail inventory levels and a reduction in dedicated shelf space in the wake of new private label and competitive entries into this market. Skin care revenues advanced 17% during the quarter and included results for the recently introduced Curel AHA product line. Eyecare products in the U.S. attained a 6% increase in sales, benefiting from incremental sales of Opcon-A, an antihistamine/decongestant, which has received good initial acceptance. Revenues for consumer oral care products were nearly 20% below the third quarter of 1994, primarily due to sluggish demand for Interplak power toothbrushes and the discontinuation of the Clear Choice line of mouthwash in the U.S. Medical sector sales rose 18% from third quarter 1994 levels. Worldwide contact lens revenues advanced 14%, led by a 45% increase in sales of planned replacement lens products, most notably in markets in the U.S., Asia and Europe. Although sales of traditional contact lenses increased in Japan, they declined modestly in the third quarter of 1994 in other areas, reflecting the general market shift toward planned replacement lenses. Worldwide revenues for rigid gas permeable (RGP) lenses and lens materials also contributed to overall contact lens growth and included sales of the new Boston 7 lens material. Worldwide ophthalmic pharmaceutical revenues improved 24%. Within the U.S., these results were attributable to the success of recently introduced products, including Tobramycin and Levobunolol, and to incremental sales of Crolom, which is indicated for seasonal allergic eye conditions. Third quarter revenues for prescription pharmaceuticals in Europe also advanced from the prior year. Increased demand was noted for the Company's lines of dental implants and hearing aids. Hearing aid revenues rose 25% in response to improved overall market conditions and encouraging consumer demand for the recently introduced Mirage completely in-the-canal product line. A new programmable hearing aid was also introduced during the quarter. A 6% improvement in the Company's biomedical sector reflected increased shipments of specific pathogen-free eggs and toxicology products, as well as increased revenues for animal operations outside the U.S. Optics Segment Revenues Due to the sale of the Company's sports optics business earlier in the year, reported optics segment revenues declined 21% and 7% for the quarter and nine-month periods, respectively. Excluding sports optics results from these comparisons, optics segment revenues grew 1% for the third quarter and 5% for the first nine months. Revenue increases were evidenced for premium-priced sunglasses, driven by strong demand for new product lines including Ray-Ban xrays and Orbs and Killer Loop Activ which more than offset a decline in demand for products with more traditional designs. These positive results were attained during a period in which this business was actively engaged in programs to develop flexible manufacturing capacity for its new products. As a result, the Company was not able to meet fully the demand created by strong global consumer acceptance of new products. The ultra-premium-priced Revo and moderately-priced sunglass lines, including Liz Claiborne and Suncloud, also experienced increased sales in the 1995 third quarter. Many new sunglass products are in the fashion and sport segments, areas where the Company is trying to increase its market presence. Products in these segments are subject, in part, to the ability to anticipate and satisfy changes in consumer preferences and are generally characterized by shorter life cycles. Being successful in these categories generally requires innovative design and marketing expertise. Net Sales By Geographic Region Sales in markets outside the U.S. totaled $228 million in the third quarter, an increase of $13 million or 6% from 1994, and represented 48% of consolidated revenues, compared to 44% in 1994. European revenues increased 12% and benefited from the favorable impact of currency movements, particularly in Germany. This progress also reflected improved demand for the Company's sunglasses, over-the-counter medications, lens care products and planned replacement lenses. Sales in Japan advanced 13%, attributable to favorable currency exchange rate fluctuations, as well as increased sales of sunglasses, contact lenses and lens care products. Elsewhere in Asia, revenues declined 3%, based on lower demand for sunglasses and the effect of the sale of the sports optics business. Revenues declined 12% in Latin America and Canada. Sales shortfalls in Mexico more than offset improvement in Brazil, where demand has increased primarily attributable to rising consumer confidence. If results for the discontinued sports optics business are excluded from these comparisons, sales in Europe and Japan each advanced 13% while revenues declined 2% in the Asia Pacific region outside Japan and in Latin America and Canada. U.S. sales totaled $248 million in the third quarter of 1995, a decrease of $22 million or 8% from 1994. Revenue increases for planned replacement contact lenses, sunglasses, pharmaceuticals and hearing aids were offset by the divestiture of the sports optics business and shortfalls for soft lens care solutions. Excluding the divested sports optics business from 1994 results, U.S. sales increased 4% over the prior year level, and reflect the impact of new product introductions as well as a closer alignment of the Company's sales to consumer purchasing patterns, particularly in the sunglass business. Costs And Expenses The ratio of the cost of products sold to sales was 43.1% for the 1995 third quarter versus 51.0% for the comparable 1994 period. For the respective nine-month periods, this ratio was 44.5% for 1995 and 47.9% for 1994. The improvement is due to shifts in sales mix toward higher- margin hearing aids and pharmaceutical products as well as the divestiture of the sports optics business and favorable impact of foreign currency exchange rate changes. These trends more than offset the impact of increased demand for lower-margin planned replacement lenses and new sunglass products. It is expected that developing new contact lens manufacturing technologies and rationalizing some current product lines should reduce the costs of producing soft contact lenses in the future. Programs to develop flexible sunglass manufacturing capacity are also expected to improve efficiencies and reduce the margin differential between traditional and new products. Selling, administrative and general expenses were 36.4% of sales in the third quarter of 1995, a decrease from 36.7% in 1994 resulting from lower advertising expenditures. For the nine-month period, these expenses were 38.9% of sales in 1995 and 37.1% of sales in 1994. The year-to-date increases reflect promotional support for the launch and test marketing of several new products. Higher levels of advertising and promotion spending in the first six months included additional support for Ray-Ban sunglasses in key markets, skin care product advertising and the establishment of a business development fund for marketing programs directed toward contact lens patients. Corporate administration expense was 2.6% of sales in 1995 versus 2.0% for the 1994 third quarter. The Company's stated objective is to manage these expenses to a targeted level of no more than 3% of sales. Research and development expense for the 1995 third quarter increased 8% from 1994 levels. 1995 spending has been primarily directed toward the support of new sunglass, contact lens, and pharmaceutical products. Restructuring Reserves In the fourth quarter of 1993, the Company announced plans to restructure its sunglass, pharmaceutical and biomedical operations and recorded a pre-tax restructuring charge of $50 million. As of September 30, 1995, $1.6 million of the original reserve remained on the Company's balance sheet. All actions contemplated at the time of establishing the reserve have been completed or are expected to be fully completed in 1995. Reserves remaining primarily represent liabilities for continuing severance payments and project expenses and are believed to be adequate. Business Segment And Operating Earnings Business segment earnings of $94 million for the 1995 third quarter improved $39 million from 1994. This primarily reflected improved operating results for oral care products, skin care products, contact lenses, hearing aids and prescription pharmaceuticals. Operating earnings totaled $82 million, an increase of $37 million from the prior year period. Other Income And Expenses Income from investments totaled $9 million for the third quarters of 1995 and 1994, as higher non-U.S. investment levels and interest rates were offset by lower income earned on an interest rate swap associated with the Wilmington Partners L.P. transaction. Interest expense of $11 million for the 1995 third quarter increased $1 million over the third quarter of 1994, despite lower debt levels, as a result of higher interest rates on U.S. borrowings. The Company recognized a net foreign currency loss of $2 million, representing a decline of $3 million from the net $1 million gain recognized in 1994. This reflected anticipated lower premium income earned on the Company's Irish pound hedge contracts in the current year. The Company's reported income tax rates for the three- and nine-month periods were 37.0% and 36.6% in 1995 compared to 33.5% and 32.8% in 1994, respectively. 1994 rates benefited from a reduction in statutory tax rates in Germany for which the Company recorded an adjustment to its deferred tax liabilities. 1995 rates reflected the increased significance of earnings in countries with relatively higher statutory rates, most notably Japan and Germany. Liquidity And Financial Resources Cash Flows Provided By Operating Activities Cash flows provided by operating activities totaled $200 million through September 1995, an increase of $44 million from the prior year period. This improvement was primarily attributable to cash realized from the net settlement of foreign currency hedge contracts, the comparisons against significant restructuring actions completed in 1994 and the timing of payments for advertising and promotion. These factors were moderated by the positive cash flow in 1994 generated by collections on receivables outstanding at the end of 1993. Cash Flows Provided By Investing Activities Cash flows provided by investing activities improved $551 million from 1994 to $15 million. Purchases of property, plant and equipment totaled $58 million, a decrease of $5 million from 1994. Higher capital spending in the prior year was primarily in support of the development of new contact lens technology. Major projects in 1995 include new cast mold capacity for contact lenses and manufacturing improvements for sunglasses in the U.S., Europe and Asia-Pacific regions. Other investing activities in the first nine months of 1994 included the acquisition of the assets of Revo, Inc., a U.S.-based manufacturer of high performance sunglasses and the investment of $425 million in securities of a wholly-owned subsidiary of a triple-A rated financial institution, while in 1995, the reported net inflows of cash included amounts received from the divestiture of the Company's sports optics business, from a deposit refund and from collections of notes receivable. Cash Flows Used In Financing Activities Approximately $166 million in cash was used in financing activities, including repurchases of the Company's Common shares, the payment of dividends and repayments of U.S. promissory notes. Free Cash Flow The Company has continued to improve cash flow and reduce its working capital requirements. The Company's goal is to maximize free cash flow which is defined as cash generated before dividends, the repayment of debt, stock repurchases and the acquisition or divestiture of businesses. Free cash flow for the nine months ended September 30, 1995 totaled $154 million. For the nine months ended September 24, 1994 free cash flow totaled $95 million. The increase over the prior year is primarily attributable to changes in other current assets and accrued liabilities levels and lower capital expenditures described previously. Financial Position The Company's total debt, consisting of short- and long-term borrowings, decreased by $46 million from year-end 1994 to $544 million at the end of the 1995 third quarter. Bausch & Lomb's ratio of total debt to equity stood at 57% in September 1995 and 62% in September 1994. Cash and investments totaled $285 million and $194 million at the end of the third quarters of 1995 and 1994, respectively. Access to Financial Markets To support its liquidity requirements, the Company maintains U.S. revolving credit agreements, typically with 364-day credit terms, totaling $290 million. The interest rate under the agreements is at the prime rate, or, at the Company's option, at a mutually acceptable market rate. No debt was outstanding under these agreements at September 30, 1995 nor were there any borrowings outstanding under the Company's $300 million medium-term note program. The Company also maintains bank lines of credit for its financing requirements. The availability of adequate credit facilities provides the Company with a high degree of flexibility to meet its obligations, fund capital expenditures and invest in growth opportunities. Working Capital Working capital amounted to $262 million for the third quarter of 1995, versus $277 million at year-end 1994 and $301 million for the third quarter of 1994. The current ratio was 1.4 at September 30, 1995, December 31, 1994 and September 24, 1994. OTHER FINANCIAL DATA Dividends declared on Common stock were $0.26 per share in the third quarter of 1995 and $0.245 per share in the third quarter of 1994. As a result of the goodwill impairment charge recorded in December 1994 and lower earnings performance reported during the most recent twelve-month period, the return on average shareholders' equity for the twelve-month period ended September 30, 1995 was 6%. This return was 11% for the twelve-month period ended September 24, 1994. Excluding goodwill impairment and restructuring charges, the return on average shareholders' equity would have been 11% in 1995 versus 14% in 1994. OUTLOOK Worldwide sales for many of the Company's products are expected to continue to show year-over-year growth for the remainder of 1995. Within the lens care products category, success in the important U.S. market is dependent on a rebound in shipments to retail customers. Additionally, overall Company growth is dependent on the ability to meet consumer demand for new sunglass products. The positive effect of changes in foreign currency exchange rates noted earlier in 1995 has lessened, and there can be no assurance that these trends will continue into the fourth quarter. The Company also continues to monitor the effect of adverse economic trends in certain markets, particularly in Latin America. For contact lenses, manufacturing capacity for the Company's next generation of planned replacement lenses will be increased. The Company has previously announced that it will commit a total of more than $30 million in this area. This increased capacity will allow the Company to capitalize on consumer trends toward this type of lens product, and reduce contact lens manufacturing costs beyond 1995. As noted earlier, the increasing significance of earnings in Japan and Germany have increased the Company's reported tax rate for the first nine months of 1995, and this trend is expected to continue. PART II - OTHER INFORMATION Item 1. Legal Proceedings. In its 1994 Annual Report on Form 10-K and its first and second quarter 1995 Forms 10-Q the Company reported on proposed class actions filed in Pennsylvania, New Jersey, New York and California state courts, alleging that the Company misled consumers in its marketing and sale of Sensitive Eyes Saline and Rewetting Drops, Boston Rewetting Drops and Conditioning Solution and the Company's eyewash product. On September 12, 1995, the Company entered into a stipulation in the New York case, certifying a nationwide class of consumers of Sensitive Eyes Rewetting Drops, Boston Rewetting Drops, Bausch & Lomb Eyewash and ReNu Rewetting Drops for the period May 1, 1989 to June 30, 1995, which is awaiting court approval. A similar action has been moved from federal to state court in California and has been temporarily stayed pending further developments in the New York case. In each of these matters, the Company is defending itself vigorously in part on the basis that the Company's actions were in compliance with applicable FDA regulations. In its 1994 Annual Report on Form 10-K, the Company described proposed shareholder class actions involving purchasers of stock between December 14, 1993 and June 3, 1994 and between June 4, 1994 and January 25, 1995. The suits claim the Company did not fully disclose information about expected future financial results, thus misleading its shareholders. On September 25, 1995, the plaintiffs in these actions consolidated their claims and filed a second amended consolidated complaint. The Company continues to vigorously defend against these claims. Item 6. Exhibits and Reports on Form 8-K. (a) Item 601 Exhibits Those exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits filed herewith and such listing is incorporated herein by reference. (b) Reports on Form 8-K No reports on Form 8-K were filed during the quarter for which this Report is filed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BAUSCH & LOMB INCORPORATED Date: March 15, 1996 By: (Jay T. Holmes) Jay T. Holmes Executive Vice President and Chief Administrative Officer Date: March 15, 1996 By: (Stephen C. McCluski) Stephen C. McCluski Senior Vice President, Finance EXHIBIT INDEX S-K Item 601 No. Document (4)-a Certificate of Incorporation of Bausch & Lomb Incorporated (filed as Exhibit (4)-a to the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 1985, File No. 1- 4105, and incorporated herein by reference). (4)-b Certificate of Amendment of Bausch & Lomb Incorporated (filed as Exhibit (4)-b to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1988, File No. 1- 4105, and incorporated herein by reference). (4)-c Certificate of Amendment of Bausch & Lomb Incorporated (filed as Exhibit (4)-c to the Company's Annual Report on Form 10-K for the fiscal year ended December 26, 1992, File No. 1- 4105, and incorporated herein by reference). (4)-d Form of Indenture, dated as of September 1, 1991, between the Company and Citibank, N.A., as Trustee, with respect to the Company's Medium- Term Notes (filed as Exhibit (4)-a to the Company's Registration Statement on Form S-3, File No. 33-42858, and incorporated herein by reference). (4)-e Rights Agreement between the Company and The First National Bank of Boston, as successor to Chase Lincoln First Bank, N.A. (filed as Exhibit 1 to the Company's Current Report on Form 8-K dated July 25, 1988, File No. 1-4105, and incorporated herein by reference). (4)-f Amendment to the Rights Agreement between the Company and The First National Bank of Boston, as successor to Chase Lincoln First Bank, N.A. (filed as Exhibit 1 to the Company's Current Report on Form 8-K dated July 31, 1990, File No. 1-4105, and incorporated herein by reference). (11) Statement Regarding Computation of Per Share Earnings (filed herewith). (12) Statement Regarding Computation of Ratio of Earnings to Fixed Charges (filed herewith). (27) Financial Data Schedule (filed herewith) Exhibit 11 Statement Regarding Computation of Per Share Earnings Dollars And Shares In Thousands- Except Per Share Data
NINE MONTHS ENDED September 30 September 24 1995 1994* Net earnings $115,387 $93,199 ======== ======= Actual outstanding Common shares at beginning of year 58,992 59,118 Average Common shares issued for stock options and effects of assumed exercise of common stock equivalents and repurchase of Common shares (745) 669 ------- ------ Average Common shares outstanding 58,247 59,787 ======= ====== Net earnings per Common and common share equivalent $ 1.98 $ 1.56 ======= ====== *Results have been restated as more fully described in Note A - "Restatement of Financial Information".
Exhibit 12 Statement Regarding Computation of Ratio of Earnings to Fixed Charges Dollar Amounts In Thousands
September 30, December 31, 1995 1994* Earnings before provision for income taxes and minority interest $207,011 $116,342 Fixed charges 36,420 42,954 Capitalized interest, net of current period amortization 195 260 ------- ------- Total earnings as adjusted $243,626 $159,556 ======= ======= Fixed charges: Interest (including interest expense and capitalized interest) $ 34,999 $ 41,379 Portion of rents representative of the interest factor 1,421 1,575 ------- ------- Total fixed charges $ 36,420 $ 42,954 ======= ======= Ratio of earnings to fixed charges 6.69 3.71 ======= ======= *Results have been restated as more fully described in Note A - "Restatement of Financial Information". Excluding the effect of the goodwill impairment charge recorded in the fourth quarter of 1994, the ratio of earnings to fixed charges at December 31, 1994 would have been 5.46.
EX-27 2 WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.
5 9-MOS QTR-3 DEC-30-1995 DEC-30-1995 SEP-30-1995 SEP-30-1995 283,930 283,930 942 942 279,912 279,912 13,304 13,304 303,958 303,958 1,003,340 1,003,340 1,066,764 1,066,764 525,541 525,541 2,499,912 2,499,912 740,915 740,915 231,670 231,670 24,181 24,181 0 0 0 0 934,721 934,721 2,499,912 2,499,912 1,477,817 476,757 1,477,817 476,757 657,949 205,495 657,949 205,495 622,341 189,745 5,415 63 34,999 11,013 207,011 77,520 75,744 28,682 115,387 43,514 0 0 0 0 0 0 115,387 43,514 1.98 .75 1.98 .75 Income Before Taxes and Minority Interest
-----END PRIVACY-ENHANCED MESSAGE-----